The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts - Concepedia

Concepedia

Publication | Open Access

The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts

DOI Full Paper Access

94

Citations

21

References

2006

Year

Lova Segerström, D. Fuchs, Ulrika Bäckman, Kajsa Holmquist, Rolf Christofferson, Faranak Azarbayjani

Pediatric Research

AngiogenesisGrowth RateImmunologyPathologyImmune Checkpoint InhibitorMedicineCancer GrowthCancer ResearchTumor BiologyHigh-risk Neuroblastoma Xenografts

References

	Year	Citations

Page 1